Shares of the South Korea-based AbClon Inc surged on their debut on the Kosdaq market aided by the encouraging outlook for its broad antibody pipeline and platform technology as well as recent positive market sentiment towards pharma/biotech stocks. shines
The shares gained 41% during the first three days of trading since their debut on Sept. 18. AbClon raised KRW6.8bn...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


